1.
Great Britain. Audit Commission for Local Authorities and the National Health Service in England and Wales. What Seems to Be the Matter Communication (National Health Service Report) [Paperback]. Stationery Office. Available from: https://webarchive.nationalarchives.gov.uk/20150410163038/http://archive.audit-commission.gov.uk/auditcommission/aboutus/publications/pages/national-reports-and-studies-archive.aspx.html
2.
An information leaflet for surgical patients. Annals of The Royal College of Surgeons of England [Internet]. 1983;65(4). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2494353/
3.
Department of Health. Toolkit for Producing Patient Information, Version 2 [Internet]. London: Crown copyright; 2003. Available from: https://www.uea.ac.uk/documents/246046/0/Toolkit+for+producing+patient+information.pdf
4.
Garner M, Ning Z, Francis J. A framework for the evaluation of patient information leaflets. Health Expectations. 2012 Sep;15(3):283–94. doi:10.1111/j.1369-7625.2011.00665.x
5.
Prescription information leaflets: a pilot study in general practice. British Medical Journal (Clinical research ed) [Internet]. 1983;287(6400). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1549423/
6.
Berthelsen MP, Husu E, Christensen SB, Prahm KP, Vissing J, Jensen BR. Anti-gravity training improves walking capacity and postural balance in patients with muscular dystrophy. Neuromuscular Disorders. 2014 Jun;24(6):492–8. doi:10.1016/j.nmd.2014.03.001
7.
Cup EH, Pieterse AJ, ten Broek-Pastoor JM, Munneke M, van Engelen BG, Hendricks HT, et al. Exercise Therapy and Other Types of Physical Therapy for Patients With Neuromuscular Diseases: A Systematic Review. Archives of Physical Medicine and Rehabilitation. 2007 Nov;88(11):1452–64. doi:10.1016/j.apmr.2007.07.024
8.
Voet NB, van der Kooi EL, Riphagen II, Lindeman E, van Engelen BG, Geurts AC. Strength training and aerobic exercise training for muscle disease. Cochrane Database of Systematic Reviews. 2013 Jul 9. doi:10.1002/14651858.CD003907.pub4
9.
Sveen ML, Andersen SP, Ingelsrud LH, Blichter S, Olsen NE, Jønck S, et al. Resistance training in patients with limb-girdle and becker muscular dystrophies. Muscle & Nerve. 2013 Feb;47(2):163–9. doi:10.1002/mus.23491
10.
Jeppesen TD, Schwartz M, Olsen DB, Wibrand F, Krag T, Duno M, et al. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain. 2006 Jun 9;129(12):3402–12. doi:10.1093/brain/awl149
11.
Balance and walking involvement in facioscapulohumeral dystrophy: a pilot study on the effects of custom lower limb orthoses - European Journal of Physical and Rehabilitation Medicine 2013 April;49(2):169-78 - Minerva Medica - Journals [Internet]. Available from: https://www.minervamedica.it/en/journals/europa-medicophysica/article.php?cod=R33Y2013N02A0169
12.
Institute of Neurology, Queen Square, National Hospital for Neurology and Neurosurgery (London, England). Neurology: a Queen Square textbook [Internet]. Second edition. Clarke C, Howard R, Rossor M, Shorvon SD, editors. Chichester, West Sussex, UK: John Wiley & Sons, Inc; 2016. Available from: https://onlinelibrary.wiley.com/doi/book/10.1002/9781118486160
13.
Neuromuscular Disease Center [Internet]. Available from: https://neuromuscular.wustl.edu/
14.
Barohn RJ, Dimachkie MM, Jackson CE. A Pattern Recognition Approach to Patients with a Suspected Myopathy. Neurologic Clinics. 2014 Aug;32(3):569–93. doi:10.1016/j.ncl.2014.04.008
15.
Jones DA, Haan A de, Round JM. Skeletal muscle from molecules to movement: a textbook of muscle physiology for sport, exercise, physiotherapy and medicine. Edinburgh: Churchill Livingstone; 2004.
16.
By:Gordon, AM (Gordon, AM); Homsher, E (Homsher, E); Regnier, M (Regnier, M). Regulation of contraction in striated muscle. PHYSIOLOGICAL REVIEWS PHYSIOLOGICAL REVIEWS [Internet]. 2000;80(2):853–924. Available from: http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=GeneralSearch&qid=13&SID=C49BOGnSGP9s3PqA3ow&page=1&doc=1
17.
Force-velocity properties of human skeletal muscle fibres: myosin heavy chain isoform and temperature dependence. The Journal of Physiology [Internet]. 1996;495(Pt 2). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1160815/
18.
Harridge SDR, Bottinelli R, Canepari M, Pellegrino MA, Reggiani C, Esbjörnsson M, et al. Whole-muscle and single-fibre contractile properties and myosin heavy chain isoforms in humans. Pflügers Archiv - European Journal of Physiology. 1996 Sep;432(5):913–20. doi:10.1007/s004240050215
19.
Hunter S, White M, Thompson M. Techniques to Evaluate Elderly Human Muscle Function: A Physiological Basis. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 1998 May 1;53A(3):B204–16. doi:10.1093/gerona/53A.3.B204
20.
O’Brien TD, Reeves ND, Baltzopoulos V, Jones DA, Maganaris CN. In vivo measurements of muscle specific tension in adults and children. Experimental Physiology. 2010 Jan 1;95(1):202–10. doi:10.1113/expphysiol.2009.048967
21.
Atherton PJ, Smith K. Muscle protein synthesis in response to nutrition and exercise. The Journal of Physiology. 2012 Mar 1;590(5):1049–57. doi:10.1113/jphysiol.2011.225003
22.
Baar K. Using Molecular Biology to Maximize Concurrent Training. Sports Medicine. 2014 Nov;44(S2):117–25. doi:10.1007/s40279-014-0252-0
23.
Rennie MJ, Wackerhage H, Spangenburg EE, Booth FW. Control of the Size of the Human Muscle Mass. Annual Review of Physiology. 2004 Mar;66(1):799–828. doi:10.1146/annurev.physiol.66.052102.134444
24.
Kadi F. Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement. British Journal of Pharmacology. 2008 Jun;154(3):522–8. doi:10.1038/bjp.2008.118
25.
Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. British Journal of Pharmacology. 2008 Jun;154(3):557–68. doi:10.1038/bjp.2008.153
26.
Marcotte GR, West DWD, Baar K. The Molecular Basis for Load-Induced Skeletal Muscle Hypertrophy. Calcified Tissue International. 2015 Mar;96(3):196–210. doi:10.1007/s00223-014-9925-9
27.
Egner IM, Bruusgaard JC, Eftestøl E, Gundersen K. A cellular memory mechanism aids overload hypertrophy in muscle long after an episodic exposure to anabolic steroids. The Journal of Physiology. 2013 Dec 15;591(24):6221–30. doi:10.1113/jphysiol.2013.264457
28.
Atherton PJ, Smith K. Muscle protein synthesis in response to nutrition and exercise. The Journal of Physiology. 2012 Mar 1;590(5):1049–57. doi:10.1113/jphysiol.2011.225003
29.
Fitts RH, Trappe SW, Costill DL, Gallagher PM, Creer AC, Colloton PA, et al. Prolonged space flight-induced alterations in the structure and function of human skeletal muscle fibres. The Journal of Physiology. 2010 Sep 15;588(18):3567–92. doi:10.1113/jphysiol.2010.188508
30.
By:Jones, SW (Jones, SW); Hill, RJ (Hill, RJ); Krasney, PA (Krasney, PA); O’Conner, B (O’Conner, B); Peirce, N (Peirce, N); Greenhaff, PL (Greenhaff, PL). Disuse atrophy and exercise rehabilitation in humans profoundly affects the expression of genes associated with the regulation of skeletal muscle mass. FASEB JOURNAL FASEB JOURNAL. 2004;18(6). doi:10.1096/fj.03-1228fje
31.
Rennie MJ, Wackerhage H, Spangenburg EE, Booth FW. Control of the Size of the Human Muscle Mass. Annual Review of Physiology. 2004 Mar;66(1):799–828. doi:10.1146/annurev.physiol.66.052102.134444
32.
Shavlakadze T, Grounds M. Of bears, frogs, meat, mice and men: complexity of factors affecting skeletal muscle mass and fat. BioEssays. 2006 Oct;28(10):994–1009. doi:10.1002/bies.20479
33.
Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, et al. Acute Skeletal Muscle Wasting in Critical Illness. JAMA. 2013 Oct 16;310(15). doi:10.1001/jama.2013.278481
34.
Wiggs MP. Can endurance exercise preconditioning prevention disuse muscle atrophy? Frontiers in Physiology. 2015 Mar 11;6. doi:10.3389/fphys.2015.00063
35.
Baar K. Using Molecular Biology to Maximize Concurrent Training. Sports Medicine. 2014 Nov;44(S2):117–25. doi:10.1007/s40279-014-0252-0
36.
Craig DM, Ashcroft SP, Belew MY, Stocks B, Currell K, Baar K, et al. Utilizing small nutrient compounds as enhancers of exercise-induced mitochondrial biogenesis. Frontiers in Physiology. 2015 Oct 27;6. doi:10.3389/fphys.2015.00296
37.
Hoier B, Hellsten Y. Exercise-Induced Capillary Growth in Human Skeletal Muscle and the Dynamics of VEGF. Microcirculation. 2014 May;21(4):301–14. doi:10.1111/micc.12117
38.
Hardie DG, Sakamoto K. AMPK: A Key Sensor of Fuel and Energy Status in Skeletal Muscle. Physiology. 2006 Feb;21(1):48–60. doi:10.1152/physiol.00044.2005
39.
Hawley JA, Hargreaves M, Joyner MJ, Zierath JR. Integrative Biology of Exercise. Cell. 2014 Nov;159(4):738–49. doi:10.1016/j.cell.2014.10.029
40.
Briggs D, Morgan JE. Recent progress in satellite cell/myoblast engraftment - relevance for therapy. FEBS Journal. 2013 Sep;280(17):4281–93. doi:10.1111/febs.12273
41.
Zammit PS, Golding JP, Nagata Y, Hudon V, Partridge TA, Beauchamp JR. Muscle satellite cells adopt divergent fates. The Journal of Cell Biology. 2004 Aug 2;166(3):347–57. doi:10.1083/jcb.200312007
42.
Boldrin L, Morgan JE. Activating muscle stem cells: therapeutic potential in muscle diseases. Current Opinion in Neurology. 2007 Oct;20(5):577–82. doi:10.1097/WCO.0b013e3282ef5919
43.
Boldrin L, Zammit PS, Morgan JE. Satellite cells from dystrophic muscle retain regenerative capacity. Stem Cell Research. 2015 Jan;14(1):20–9. doi:10.1016/j.scr.2014.10.007
44.
Ross J, Benn A, Jonuschies J, Boldrin L, Muntoni F, Hewitt JE, et al. Defects in Glycosylation Impair Satellite Stem Cell Function and Niche Composition in the Muscles of the Dystrophic Large Mouse. STEM CELLS. 2012 Oct;30(10):2330–41. doi:10.1002/stem.1197
45.
Neuropathology and Applied Neurobiology [Internet]. Volume 43, Issue 1. Volume 43, Issue 1. Available from: https://onlinelibrary.wiley.com/toc/13652990/2017/43/1
46.
Dubowitz V, Sewry CA, Oldfors A. Muscle biopsy: a practical approach. Fourth edition. [Philadelphia, Pa.]: Saunders Elsevier; 2013.
47.
Hollingsworth KG, de Sousa PL, Straub V, Carlier PG. Towards harmonization of protocols for MRI outcome measures in skeletal muscle studies: Consensus recommendations from two TREAT-NMD NMR workshops, 2 May 2010, Stockholm, Sweden, 1–2 October 2009, Paris, France. Neuromuscular Disorders. 2012 Oct;22:S54–67. doi:10.1016/j.nmd.2012.06.005
48.
Wattjes MP, Fischer D. Neuromuscular imaging [Electronic resource]. New York: Springer; 2013. Available from: http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=3320980190004761&institutionId=4761&customerId=4760
49.
Forbes SC, Willcocks RJ, Triplett WT, Rooney WD, Lott DJ, Wang DJ, et al. Magnetic Resonance Imaging and Spectroscopy Assessment of Lower Extremity Skeletal Muscles in Boys with Duchenne Muscular Dystrophy: A Multicenter Cross Sectional Study. PLoS ONE. 2014 Sep 9;9(9). doi:10.1371/journal.pone.0106435
50.
Glover GH, Schneider E. Three-point dixon technique for true water/fat decomposition withB0 inhomogeneity correction. Magnetic Resonance in Medicine. 1991 Apr;18(2):371–83. doi:10.1002/mrm.1910180211
51.
Willcocks RJ, Rooney WD, Triplett WT, Forbes SC, Lott DJ, Senesac CR, et al. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort. Annals of Neurology. 2016 Apr;79(4):535–47. doi:10.1002/ana.24599
52.
Hogrel JY, Wary C, Moraux A, Azzabou N, Decostre V, Ollivier G, et al. Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophy. Neurology. 2016 Mar 15;86(11):1022–30. doi:10.1212/WNL.0000000000002464
53.
Kim HK, Serai S, Lindquist D, Merrow AC, Horn PS, Kim DH, et al. Quantitative Skeletal Muscle MRI: Part 2, MR Spectroscopy and T2 Relaxation Time Mapping—Comparison Between Boys With Duchenne Muscular Dystrophy and Healthy Boys. American Journal of Roentgenology. 2015 Aug;205(2):W216–23. doi:10.2214/AJR.14.13755
54.
Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. The Lancet Neurology. 2003 Dec;2(12):731–40. doi:10.1016/S1474-4422(03)00585-4
55.
Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. The Lancet Neurology. 2010 Jan;9(1):77–93. doi:10.1016/S1474-4422(09)70271-6
56.
Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. The Lancet Neurology. 2010 Feb;9(2):177–89. doi:10.1016/S1474-4422(09)70272-8
57.
Ricotti V, Ridout DA, Scott E, Quinlivan R, Robb SA, Manzur AY, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. Journal of Neurology, Neurosurgery & Psychiatry. 2013 Jun 1;84(6):698–705. doi:10.1136/jnnp-2012-303902
58.
Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, et al. Systemic Administration of PRO051 in Duchenne’s Muscular Dystrophy. New England Journal of Medicine. 2011 Apr 21;364(16):1513–22. doi:10.1056/NEJMoa1011367
59.
Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Annals of Neurology. 2013 Nov;74(5):637–47. doi:10.1002/ana.23982
60.
Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Annals of Neurology. 2016 Feb;79(2):257–71. doi:10.1002/ana.24555
61.
Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. The Lancet Neurology. 2009 Oct;8(10):918–28. doi:10.1016/S1474-4422(09)70211-X
62.
Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. The Lancet. 2011 Aug;378(9791):595–605. doi:10.1016/S0140-6736(11)60756-3
63.
Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle & Nerve. 2014 Oct;50(4):477–87. doi:10.1002/mus.24332
64.
Paganoni S, Amato A. Electrodiagnostic Evaluation of Myopathies. Physical Medicine and Rehabilitation Clinics of North America. 2013 Feb;24(1):193–207. doi:10.1016/j.pmr.2012.08.017
65.
Fuglsang-Frederiksen A. The role of different EMG methods in evaluating myopathy. Clinical Neurophysiology. 2006 Jun;117(6):1173–89. doi:10.1016/j.clinph.2005.12.018
66.
Machado P, Brady S, Hanna MG. Update in inclusion body myositis. Current Opinion in Rheumatology. 2013 Nov;25(6):763–71. doi:10.1097/01.bor.0000434671.77891.9a
67.
Machado PM, Dimachkie MM, Barohn RJ. Sporadic inclusion body myositis. Current Opinion in Neurology. 2014 Oct;27(5):591–8. doi:10.1097/WCO.0000000000000129
68.
Machado PM, Ahmed M, Brady S, Gang Q, Healy E, Morrow JM, et al. Ongoing Developments in Sporadic Inclusion Body Myositis. Current Rheumatology Reports. 2014 Dec;16(12). doi:10.1007/s11926-014-0477-9
69.
Ahmed M, Machado PM, Miller A, Spicer C, Herbelin L, He J, et al. Targeting protein homeostasis in sporadic inclusion body myositis. Science Translational Medicine. 2016 Mar 23;8(331):331ra41-331ra41. doi:10.1126/scitranslmed.aad4583
70.
Needham M, Mastaglia FL. Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment. Clinical Neurophysiology. 2016 Mar;127(3):1764–73. doi:10.1016/j.clinph.2015.12.011
71.
Schröder R, Schoser B. Myofibrillar Myopathies: A Clinical and Myopathological Guide. Brain Pathology. 2009 Jul;19(3):483–92. doi:10.1111/j.1750-3639.2009.00289.x
72.
Amato AA, Greenberg SA. Inflammatory Myopathies. CONTINUUM: Lifelong Learning in Neurology. 2013 Dec;19:1615–33. doi:10.1212/01.CON.0000440662.26427.bd
73.
Olivé M, Kley RA, Goldfarb LG. Myofibrillar myopathies. Current Opinion in Neurology. 2013 Oct;26(5):527–35. doi:10.1097/WCO.0b013e328364d6b1
74.
Carstens PO, Schmidt J. Diagnosis, pathogenesis and treatment of myositis: recent advances. Clinical & Experimental Immunology. 2014 Mar;175(3):349–58. doi:10.1111/cei.12194
75.
Dalakas MC. Inflammatory Muscle Diseases. New England Journal of Medicine. 2015 Apr 30;372(18):1734–47. doi:10.1056/NEJMra1402225
76.
Darras BT, De Vivo DC, Jones HR. Neuromuscular disorders of infancy, childhood, and adolescence: a clinician’s approach. Philadelphia, Penn. ; London: Butterworth-Heinemann; 2003.
77.
Baioni MTC, Ambiel CR. Spinal muscular atrophy: diagnosis, treatment and future prospects. Jornal de Pediatria. 2010 Aug 11;86(4):261–70. doi:10.2223/JPED.1988
78.
Rudnik-Schöneborn S, Hausmanowa-Petrusewicz I, Borkowska J, Zerres K. The Predictive Value of Achieved Motor Milestones Assessed in 441 Patients with Infantile Spinal Muscular Atrophy Types II and III. European Neurology. 2001;45(3):174–81. doi:10.1159/000052118
79.
Russman BS, Buncher CR, White M, Samaha FJ, Iannaccone ST. Function changes in spinal muscular atrophy II and III. Neurology. 1996 Oct 1;47(4):973–6. doi:10.1212/WNL.47.4.973
80.
Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al. Consensus Statement for Standard of Care in Spinal Muscular Atrophy. Journal of Child Neurology. 2007 Aug;22(8):1027–49. doi:10.1177/0883073807305788
81.
Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. The Lancet Neurology. 2012 May;11(5):443–52. doi:10.1016/S1474-4422(12)70061-3
82.
Hollak CEM, Lachmann R, editors. Inherited Metabolic Disease in Adults [Internet]. Vol. 1. Oxford University Press; 2016. Available from: http://www.oxfordmedicine.com/view/10.1093/med/9780199972135.001.0001/med-9780199972135 doi:10.1093/med/9780199972135.001.0001
83.
Nancy D Leslie. Very Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency. Gene Reviews [Internet]. 2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK6816/
84.
Thomas Wieser. Carnitine Palmitoyltransferase II Deficiency. Gene Reviews [Internet]. 2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1253/
85.
Miguel A Martín. Glycogen Storage Disease Type V. Gene Reviews [Internet]. 2014. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1344/
86.
Nancy Leslie. Pompe Disease. Gene Reviews [Internet]. 2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1261/
87.
Ørngreen MC, Vissing J. Treatment Opportunities in Patients With Metabolic Myopathies. Current Treatment Options in Neurology. 2017 Nov;19(11). doi:10.1007/s11940-017-0473-2
88.
Olpin SE, Murphy E, Kirk RJ, Taylor RW, Quinlivan R. The investigation and management of metabolic myopathies. Journal of Clinical Pathology. 2015 Jun;68(6):410–7. doi:10.1136/jclinpath-2014-202808
89.
Feingold B, Mahle WT, Auerbach S, Clemens P, Domenighetti AA, Jefferies JL, et al. Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. Circulation. 2017 Sep 26;136(13). doi:10.1161/CIR.0000000000000526
90.
Matthews E, Hanna MG. Skeletal muscle channelopathies. In: Hilton-Jones D, Turner MR, editors. Oxford Textbook of Neuromuscular Disorders [Internet]. Oxford University Press; 2014. p. 316–25. Available from: http://oxfordmedicine.com/view/10.1093/med/9780199698073.001.0001/med-9780199698073-chapter-31 doi:10.1093/med/9780199698073.003.0031
91.
Hollak CEM, Lachmann R, editors. Inherited Metabolic Disease in Adults [Internet]. Vol. 1. Oxford University Press; 2016. Available from: http://www.oxfordmedicine.com/view/10.1093/med/9780199972135.001.0001/med-9780199972135 doi:10.1093/med/9780199972135.001.0001
92.
Saudubray JM, Baumgartner MR, Walter J, editors. Inborn metabolic diseases: diagnosis and treatment. 6th edition. Berlin: Springer; 2016.
93.
Hoffmann GF, Zschocke J, Nyhan WL, editors. Inherited metabolic diseases: a clinical approach. Second edition. Berlin: Springer; 2017.
